Cancer Radiotherapie最新文献

{"title":"Évaluation de facteurs prédictifs de réponse pathologique à la radiothérapie néoadjuvante des sarcomes des tissus mous","authors":"N. Hanslik ,&nbsp;C. Bourgier ,&nbsp;S. Thezenas ,&nbsp;S. Carrère ,&nbsp;N. Firmin ,&nbsp;O. Riou ,&nbsp;D. Azria ,&nbsp;C. Llacer-Moscardo","doi":"10.1016/j.canrad.2023.02.003","DOIUrl":"10.1016/j.canrad.2023.02.003","url":null,"abstract":"<div><h3>Purpose</h3><p>Conserving surgery combined with radiotherapy in presence of local recurrence risk factors is standard treatment of soft tissue sarcomas, a group of rare and heterogeneous tumours. Radiotherapy is performed before or after surgery. In neoadjuvant setting, late radiation-induced toxicity is reduced and pathological response to radiotherapy could be achieved. A complete pathological response to radiotherapy has recently been shown to predict better survival. Our study aims at identifying predictive factors of pathological response to neoadjuvant radiotherapy (clinical, radiological or histological) of soft tissue sarcomas.</p></div><div><h3>Patients and methods</h3><p>Clinical, imaging (MRI: perilesional oedema, necrosis, tumour heterogeneity, vasculonervous relationships) and pathological (pathological subtype, tumour grade, anticipated/obtained resection quality) data were retrospectively collected. Tumour response (imaging and pathological), patient outcome, acute and late radiation-induced toxicity, predictive factors of pathological response to neoadjuvant radiotherapy were studied. The 2-test or exact-Fisher test (qualitative variables) and by Student's <em>t</em>-test or Kruskal-Wallis test (quantitative variables) were used for statistical analysis.</p></div><div><h3>Results</h3><p>From April 2017 to April 2021, neoadjuvant radiotherapy (50<!--> <!-->Gy in 25 fractions) followed by surgical excision was performed to 36 consecutive patients with liposarcomas (<em>n</em> <!-->=<!--> <!-->17/36), or undifferentiated sarcomas (<em>n</em> <!-->=<!--> <!-->8/36). MRI response was complete in 1 patient, partial in 9 patients (<em>n</em> <!-->=<!--> <!-->9/36, 25%), stable in 21 patients (<em>n</em> <!-->=<!--> <!-->21/36, 58%) or in progression in 5 patients (<em>n</em> <!-->=<!--> <!-->5/36, 14%). Pathological response was observed in 22 patients (61%). No grade 3-4 acute radiation-induced toxicity was observed. Regarding late toxicity, 28% of patients had grade 1–2 oedema (<em>n</em> <!-->=<!--> <!-->10/36), 39% had a grade 1 fibrosis (<em>n</em> <!-->=<!--> <!-->14/36), and 30% grade 1 pain (<em>n</em> <!-->=<!--> <!-->11/36). No predictive factors of response to radiotherapy was statistically significant.</p></div><div><h3>Conclusions</h3><p>Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41184509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase de consolidation (docteur junior) en oncologie–radiothérapie en France : état des lieux et perspectives","authors":"A. Larnaudie ,&nbsp;V. Bourbonne ,&nbsp;M. Michalet ,&nbsp;Q. Laune ,&nbsp;M. Delaye ,&nbsp;F. Huguet ,&nbsp;D. Azria ,&nbsp;R. Varnier ,&nbsp;Y. Ghannam","doi":"10.1016/j.canrad.2023.08.003","DOIUrl":"10.1016/j.canrad.2023.08.003","url":null,"abstract":"<div><h3>Purpose</h3><p>The last year of the radiotherapy oncology internship in France has become a phase of empowerment, called “junior doctor”, allowing interns to validate acts previously reserved only for senior doctors. This study focused on the responsibilities given to the first promotion of junior doctors in France and their feelings on this new status.</p></div><div><h3>Material and methods</h3><p>A cross-sectional survey was carried out by the French associations of interns and young doctors in oncology, Aerio and SFjRO. A questionnaire was sent to the class referents of each city for transmission to the junior doctors of the year 2021–2022 from September 1st to November 30th, 2022. The questions concerned training, the modalities of this year and the feelings. Responses were analyzed anonymously using R. 4.3.1 software.</p></div><div><h3>Results</h3><p>For radiation oncology, 33 responses were obtained from 21 cities. For most junior doctors, three to four localizations (51%) were performed with an average of five new patients per week. The contours were reviewed either systematically (51%) or only at the beginning (32%). Dosimetry was reported as never countersigned in 19%; 80% of junior doctors described having been the only radiation oncologist during multidisciplinary staff meetings. The two main areas of improvement were theoretical training (45%) and legal frameworks/contracts (42%).</p></div><div><h3>Conclusion</h3><p>These results relating to the first class of junior doctors showed an overall agreement with the recommendations of the Cnec. Feedback from interns was positive. The supervision of brachytherapy and dosimetry activities, the presence alone in multidisciplinary panel remained points of vigilance.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"61567017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of radiotherapy in the management of rare gynaecological cancers","authors":"R. Morcet-Delattre ,&nbsp;S. Espenel ,&nbsp;P. Tas ,&nbsp;C. Chargari ,&nbsp;A. Escande","doi":"10.1016/j.canrad.2023.08.006","DOIUrl":"10.1016/j.canrad.2023.08.006","url":null,"abstract":"<div><p><span>There are a large number of gynaecological cancers<span><span> with rare histologies, for which the available data are limited and usually retrospective. Because of their rarity and poor prognosis, the management of these cancers must be centralized in expert centres, for both histological diagnosis and treatment. With the exception of </span>sarcomas, most endometrial or cervical cancers with rare histologies respond to the same radiation treatment modalities than cancers with more common histologies, although there are some specificities regarding treatments such as </span></span>neuroendocrine carcinomas<span><span> (chemotherapy with platinum and etoposide, major role of surgery). For localized or locally advanced ovarian cancer, </span>external beam radiotherapy<span><span> has a role in the management of hypercalcaemic small cell carcinoma of the ovary. This article summarizes the current role of external beam radiotherapy and </span>brachytherapy<span> in the management of cancers of the uterine cervix, uterine corpus and ovaries, with rare or very rare histologies, and with localized or locally advanced stages.</span></span></span></p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combinaison de la radiothérapie interne vectorisée et de la radiothérapie externe","authors":"A.-L. Giraudet","doi":"10.1016/j.canrad.2023.08.005","DOIUrl":"10.1016/j.canrad.2023.08.005","url":null,"abstract":"<div><p>External beam radiation therapy and internal vectorized radiation therapy are two types of radiotherapy that can be used to treat cancer. They differ in the way they are administered, and the type of radiation used. Although they can be effective in treating cancer, they each have their own advantages and disadvantages, and their combination could be synergistic. Preclinical studies on combined internal and external beam radiation therapy have mainly used radiolabelled antibodies, whose bone marrow toxicity remains the limiting factor in increasing the administered activities. The use of small radioligands in clinical trials has shown to be better tolerated and more effective, which explains their rapid development. The results of preclinical studies on combined internal and external beam radiation therapy appear heterogeneous, making it impossible to determine an ideal therapeutic sequencing scheme, and complicating the transposition to clinical studies. The few clinical studies on combined internal and external beam radiation therapy available to date have demonstrated feasibility and tolerability. More work remains to be done in the fields of dosimetry and radiobiology, as well as in the sequencing of these two irradiation modalities to optimize their combination.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89721032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prévention, protection, et gestion des cyberattaques en oncologie radiothérapie : recommandations interprofessionnelles au nom de la Société française de radiothérapie oncologique","authors":"P. Giraud ,&nbsp;B. Fleury ,&nbsp;C. Le Prince ,&nbsp;A.T. Falk ,&nbsp;C. Rousse ,&nbsp;H. Hance ,&nbsp;J.-J. Santini ,&nbsp;D. Bicheron ,&nbsp;J. Palisson ,&nbsp;J.-M. Hannoun-Lévi ,&nbsp;K. Tack ,&nbsp;V. Marchesi ,&nbsp;D. Azria","doi":"10.1016/j.canrad.2023.09.001","DOIUrl":"10.1016/j.canrad.2023.09.001","url":null,"abstract":"<div><p>Cybersecurity is currently a major issue. Large hospitals are no longer the only main targets of attacks, but all healthcare organizations and establishments, without distinction of size or activities. The information system is defined as all the resources needed to collect images, store and process them with general distribution of multiple information within an organization. Systems are therefore crucial for the functioning of a medical department. Radiation oncology is one of the specialties most dependent on digital resources, for imaging, data transfer, dosimetry, treatment and so on.. Radiation oncology departments are therefore a prime target for ransomware attacks, which have increased significantly in recent years. Cybersecurity can be likened to a viral or bacterial attack. It is based on the two usual pillars of antimicrobial protection : hygiene and prophylaxis. In this article, we will detail by analogy the three classic levels of prevention of a bacillary attack: “primary prevention”, which acts upstream of the infection; “secondary prevention”, which acts at an early stage of its evolution; and “tertiary prevention”, which acts on complications and risks of recurrence. This article is the result of an interprofessional group on behalf of SFRO, the French society of radiation oncology, with the aim of helping all teams to implement safety adapted to the specificities of a radiation oncology department in France.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1278321823002111/pdfft?md5=59c7fc8fedc9593bd4afe7e725edd6c9&pid=1-s2.0-S1278321823002111-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An integrated model combined intra- and peritumoral regions for predicting chemoradiation response of non small cell lung cancers based on radiomics and deep learning","authors":"Y. Ma,&nbsp;Q. Li","doi":"10.1016/j.canrad.2023.05.005","DOIUrl":"10.1016/j.canrad.2023.05.005","url":null,"abstract":"<div><h3>Purpose</h3><p>The purpose of this study was to develop a model for predicting chemoradiation<span> response in non-small cell lung cancer (NSCLC) patients by integrating radiomics and deep-learning features and combined intra- and peritumoral regions with pre-treated CT images.</span></p></div><div><h3>Materials and methods</h3><p><span>This study enrolled 462 patients with NSCLC who received chemoradiation. On the basis of pretreated CT images, we developed three models to compare the prediction of chemoradiation: intratumoral, peritumoral and combined regions. To further illustrate each model, we established different feature integration methods: a) radiomics model with 1500 features; b) deep learning model with a multiple instance learning algorithm; c) integrated model by integrating radiomic and deep learning features. For radiomics and integrated models, support vector machine and the least absolute shrinkage and selection operator were used to extract and select features. </span>Transfer learning and max pooling algorithms were used to identify high informative features in deep learning models. We applied ten-fold cross validation in model training and testing.</p></div><div><h3>Results</h3><p>The best area under the curve (AUC) of intratumoral, peritumoral and combined models were 0.89 (95% CI, 0.74–0.93), 0.86 (95% CI, 0.75–0.92) and 0.92 (95% CI, 0.81–0.95), respectively. It indicated the importance of the peritumoral region for treatment response prediction and should be used in combination with the intratumoral region. Integrated models gave better results than models with radiomics and deep learning features alone in all regions of interest and radiomics models outperformed deep learning models in any comparative models.</p></div><div><h3>Conclusions</h3><p>The model that integrate radiomic and deep learning features and combined intra- and peritumoral regions provide valuable information in predicting treatment response of chemoradiation. It can help oncologists customize personalized clinical treatment plans for NSCLC patients.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71490011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practice-changing clinical trials in radiation oncology for gastrointestinal malignancies in 2021–2023","authors":"J. Boustani ,&nbsp;F. Huguet ,&nbsp;V. Vendrely","doi":"10.1016/j.canrad.2023.08.001","DOIUrl":"10.1016/j.canrad.2023.08.001","url":null,"abstract":"<div><p>Gastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. We provide an overview of the most important practice-changing trials that were either published or presented at the international scientific meetings in 2021–2023. Highlights included reports on three phase III trials (CONCORDE/PRODIGE 26, ARTDECO, and a study by Xu et al.) that evaluated dose escalation in the definitive setting for locally advanced oesophageal cancers, as well as two phase III trials that evaluated the role of chemotherapy (neo-AEGIS) and targeted therapy (NRG/RTOG 1010) in the neoadjuvant setting for adenocarcinoma oesophageal cancers or gastroesophageal junction cancer. CheckMate 577 evaluated nivolumab in patients who had residual pathological disease after neoadjuvant chemoradiation followed by complete resection. The use of radiation therapy for borderline and locally advanced pancreatic cancer is also discussed (SMART and CONKO-007 trials). Stereotactic body radiation therapy followed by sorafenib was compared to sorafenib alone in patients with hepatocellular carcinoma in the NRG/RTOG 1112 study. New options in the management of rectal cancer are emerging such as total neoadjuvant treatment (PRODIGE 23, RAPIDO, PROSPECT), organ preservation (OPRA, OPERA), and the role of immunotherapy in patients with DNA mismatch-repair deficient/microsatellite instability. Finally, preliminary results of the ACT 4 trial that evaluated de-escalation in anal cancer are presented.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136159996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review","authors":"A. Kahvecioglu ,&nbsp;S. Kilickap ,&nbsp;P. Hurmuz","doi":"10.1016/j.canrad.2023.06.002","DOIUrl":"10.1016/j.canrad.2023.06.002","url":null,"abstract":"<div><p><span>Although tyrosine kinase<span><span> inhibitors (TKI) have revolutionized the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALKr-NSCLC), radiotherapy (RT) still plays an essential role for treatment of both intracranial and extracranial metastases, particularly for patients experienced a TKI-failure. We reported the case of a 38-year-old woman with metastatic ALKr-NSCLC who received whole-brain radiotherapy (RT) for multiple brain metastases (BMs), initially. After RT, </span>alectinib was initiated and the patient had a good clinico-radiological response in both intracranial and extracranial regions. However, intracranial progression was developed and, stereotactic radiosurgery (SRS) was applied to the four progressed BMs. Two months after SRS, all BMs disappeared. While patient was using alectinib, a recurrent lung lesion, a hilar lymph node and bone metastasis were detected. Stereotactic body radiotherapy (SBRT) was applied to all metastatic sites and, alectinib was continued again. Three months after SBRT, a complete response was obtained. She has been alive with the initial systemic therapy agent for more than 4</span></span> <!-->years without evidence of neither disease nor toxicity. SRS/SBRT may eradicate the TKI-resistant tumoral clones and it may prevent switching the systemic therapy, even if there is a failure.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41223559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RadioTransNet, Radiotherapy Translational and Preclinical Research Network: Results from the dedicated French cancer institute (INCa) call for projects","authors":"É. Bayart ,&nbsp;R. De Crevoisier ,&nbsp;A. Laprie ,&nbsp;F. Milliat ,&nbsp;Y. Prezado ,&nbsp;V. Marchesi ,&nbsp;P. Maingon","doi":"10.1016/j.canrad.2023.06.019","DOIUrl":"10.1016/j.canrad.2023.06.019","url":null,"abstract":"<div><h3>Purpose</h3><p><span>The RadioTransNet project is a French initiative structuring preclinical and translational research in radiation therapy for cancer at national level. The network's activities are organized around four chosen priorities, which are: target definition, normal tissue, combined </span>treatments<span><span><span> and dose modelling. The subtargets linked to these four major priorities are unlimited. They include all aspects associated with fundamental radiobiology, </span>preclinical studies<span>, imaging, medical physics research and transversal components clearly related to these scientific areas, such as </span></span>medical oncology, radio-diagnostics, nuclear medicine and cost-effectiveness considerations.</span></p></div><div><h3>Method</h3><p>During its first phase of activity, four workshops following the consensus conference model and based on scientific and medical state of the art in radiotherapy and radiobiology were organized on the four above-mentioned objectives to identify key points. Then a road map has been defined and served as the basis for the opening in 2022 of a dedicated call, SEQ-RTH22, proposed by the French cancer national institute (INCa).</p></div><div><h3>Results</h3><p>Four research projects submitted by RadioTransNet partners have been selected to be supported by INCa: the first by Professor Anne Laprie from Oncopole Claudius-Regaud and Inserm ToNic in Toulouse on neurocognition and health after pediatric<span> irradiation, the second submitted by Fabien Milliat from IRSN aims to study decryption and targeting of endothelial cell–immune cells interactions to limit radiation-induced intestinal toxicity, the third project, submitted by Yolanda Prezado from institut Curie–CNRS on proton minibeam radiotherapy as a new approach to reduce toxicity, and the latest project proposed by R. de Crevoisier from centre Eugène-Marquis in Rennes on predictive multiscale models of head and neck radiotoxicity induced for optimized personalized radiation therapy. Topics of each of these projects are presented here.</span></p></div><div><h3>Conclusion</h3><p><span>RadioTransNet project has been launched in 2018, supported by INCa, in order to structure and promote preclinical research in oncology radiotherapy and to favor collaboration between the actors of this research. INCa relied on RadioTransNet initiatives and activities, resulting in the opening of dedicated call for projects. Beyond its first main goals, RadioTransNet network is able to help to fund the human and technical resources necessary to conduct optimal translational and preclinical research in </span>radiation oncology.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10575168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enjeux éthiques de l’information en oncologie radiothérapie : penser le risque et construire l’alliance thérapeutique","authors":"T. Haaser ,&nbsp;L. Lahmi ,&nbsp;D. Osman ,&nbsp;C. Gesbert ,&nbsp;V. Cheval ,&nbsp;Y. Constantinides ,&nbsp;R. de Crevoisier ,&nbsp;C. Dejean ,&nbsp;A. Escande ,&nbsp;Y. Ghannam ,&nbsp;F. Lorchel ,&nbsp;S. Thureau ,&nbsp;J.L. Lagrange ,&nbsp;C. Durdux ,&nbsp;F. Huguet ,&nbsp;Commission éthique de la SFRO","doi":"10.1016/j.canrad.2023.06.006","DOIUrl":"https://doi.org/10.1016/j.canrad.2023.06.006","url":null,"abstract":"<div><p>Informing patients before receiving radiation therapy is a fundamental ethical imperative. As a condition of the possibility of autonomy, information allows people to make health decisions concerning themselves, which is required by French law. This information includes in particular the potential risks due to radiation therapy. It is therefore necessary to think about what risk is, and how to define and assess it, in order to finally communicate it. The practice of informing people involves many ethical issues relating to the very content of the information, the form in which it is transmitted or even the intention that leads the health professional to say (or not to say) the risk. The transmission of information also questions the way to build a relationship of trust with the patients and how to integrate their own representations about these treatments. Between the risks of paternalism or even defensive medicine, this practice is at the heart of our professional practice.</p></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49780682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}